Donna Mery, MD
Family Medicine · Weslaco, TXNPI 1851364061
Payments from drug & device makers
Across 94 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$417
- AstraZeneca$291
- Novo Nordisk$235
- Sanofi-aventis U.S. LLC$200
- Amarin Pharma, Inc.$195
- Johnson & Johnson$192
- plus $679 from 12 others
What the payments were for
- Speaking & faculty fees$34816%
- Food & beverage$1,85584%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 8 | $417 |
| AstraZeneca | 7 | $291 |
| Novo Nordisk | 15 | $235 |
| Sanofi-aventis U.S. LLC | 8 | $200 |
| Amarin Pharma, Inc. | 5 | $195 |
| Johnson & Johnson | 4 | $192 |
| Romark Laboratories, LC | 9 | $173 |
| AbbVie(2 entities) | 7 | $117 |
| GSK | 11 | $108 |
| Lilly USA, LLC | 5 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $64 |
| Pfizer | 2 | $29 |
| Merck | 2 | $27 |
| Mannkind Corporation | 2 | $26 |
| Radius Health, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Novartis | 1 | $17 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,209 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 154 | $161,613 |
| JardianceEmpagliflozin | 91 | $99,096 |
| TrulicityDulaglutide | 41 | $41,165 |
| MyrbetriqMirabegron | 36 | $31,266 |
| XareltoRivaroxaban | 24 | $30,495 |
| MounjaroTirzepatide | 30 | $29,133 |
| TradjentaLinagliptin | 29 | $27,522 |
| EliquisApixaban | 19 | $26,310 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $25,592 |
| JanuviaSitagliptin Phosphate | 19 | $25,091 |
| LinzessLinaclotide | 13 | $17,221 |
| VascepaIcosapent Ethyl | 37 | $15,721 |
| EntrestoSacubitril/Valsartan | 12 | $13,732 |
| FarxigaDapagliflozin Propanediol | 19 | $13,528 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $12,348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $235 | $161,613154 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $70 | $70,29871 claims |
| MerckJanumet, Januvia, Janumet Xr | $27 | $63,02255 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $31,26636 claims |
| Johnson & JohnsonXarelto | $192 | $30,49524 claims |
| PfizerEliquis | $29 | $26,31019 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $108 | $22,42044 claims |
| AbbVieLinzess | $117 | $17,22113 claims |
| NovartisEntresto | $17 | $13,73212 claims |
| AstraZenecaFarxiga | $291 | $13,52819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Weslaco
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.